BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19574981)

  • 21. Depression in the medically ill.
    Harrington C
    Med Health R I; 2002 Sep; 85(9):273-7. PubMed ID: 12371211
    [No Abstract]   [Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease and diabetes mellitus.
    Adams LA
    Endocr Res; 2007; 32(3):59-69. PubMed ID: 18092195
    [No Abstract]   [Full Text] [Related]  

  • 23. The impact of systemic calcified atherosclerosis in patients with chronic kidney disease.
    McCullough PA
    Adv Chronic Kidney Dis; 2008 Oct; 15(4):335-7. PubMed ID: 18805378
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.
    Prashanth M; Ganesh HK; Vima MV; John M; Bandgar T; Joshi SR; Shah SR; Rathi PM; Joshi AS; Thakkar H; Menon PS; Shah NS
    J Assoc Physicians India; 2009 Mar; 57():205-10. PubMed ID: 19588648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Determination of risk of cardiologic complications in surgical patients].
    Kuznetsov NA
    Khirurgiia (Mosk); 1994 Jun; (6):41-2. PubMed ID: 7933889
    [No Abstract]   [Full Text] [Related]  

  • 26. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases.
    Hamer M; Chida Y; Stamatakis E
    Am J Cardiol; 2009 Aug; 104(4):538-42. PubMed ID: 19660608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comorbidity between cardiovascular disease and affective illness].
    Agelink MW; Baumann B; Sanner D; Kavuk I; Mueck-Weymann M
    Dtsch Med Wochenschr; 2004 Mar; 129(13):697-700. PubMed ID: 15026967
    [No Abstract]   [Full Text] [Related]  

  • 28. Predictors of steatohepatitis and advanced fibrosis in non-alcoholic fatty liver disease.
    Pagadala M; Zein CO; McCullough AJ
    Clin Liver Dis; 2009 Nov; 13(4):591-606. PubMed ID: 19818307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-alcoholic fatty liver disease.
    Björnsson E; Angulo P
    Scand J Gastroenterol; 2007 Sep; 42(9):1023-30. PubMed ID: 17710666
    [No Abstract]   [Full Text] [Related]  

  • 30. Fatty liver: how frequent is it and why?
    Bedogni G; Bellentani S
    Ann Hepatol; 2004; 3(2):63-5. PubMed ID: 15257248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Onset of puberty and cardiovascular risk factors in untreated obese children and adolescents: a 1-year follow-up study.
    Reinehr T; Toschke AM
    Arch Pediatr Adolesc Med; 2009 Aug; 163(8):709-15. PubMed ID: 19652102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Documentation of cardiovascular risk factors.
    McBain L
    N Z Med J; 2008 Mar; 121(1270):106. PubMed ID: 18364763
    [No Abstract]   [Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.
    Athyros VG; Katsiki N; Karagiannis A
    Angiology; 2013 Nov; 64(8):572-5. PubMed ID: 23508615
    [No Abstract]   [Full Text] [Related]  

  • 34. [The fatty liver. Pathogenesis, etiology and clinical aspects].
    Müting D
    ZFA (Stuttgart); 1981 Aug; 57(23):1554-61. PubMed ID: 7281940
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of a worksite intervention program on cardiovascular risk factors: a demonstration project in an Indian industrial population.
    Prabhakaran D; Jeemon P; Goenka S; Lakshmy R; Thankappan KR; Ahmed F; Joshi PP; Mohan BV; Meera R; Das MS; Ahuja RC; Saran RK; Chaturvedi V; Reddy KS
    J Am Coll Cardiol; 2009 May; 53(18):1718-28. PubMed ID: 19406349
    [No Abstract]   [Full Text] [Related]  

  • 36. [Risk prediction using cardiovascular magnetic resonance imaging].
    Yilmaz A; Sechtem U
    Dtsch Med Wochenschr; 2009 Oct; 134(40):2008-12. PubMed ID: 19777418
    [No Abstract]   [Full Text] [Related]  

  • 37. [Alcoholic liver diseases].
    Haas SL; Singer MV
    Dtsch Med Wochenschr; 2005 Dec; 130 Suppl 5():S223-5. PubMed ID: 16435717
    [No Abstract]   [Full Text] [Related]  

  • 38. [Evidence-based medicine and cardiovascular risk stratification aimed to drug reimbursement: uselessness of risk charts].
    Pujia A
    Ital Heart J Suppl; 2004 Aug; 5(8):661-3. PubMed ID: 15554022
    [No Abstract]   [Full Text] [Related]  

  • 39. [Metabolic syndrome as cardiovascular risk factor].
    Dłuzniewski M; Mamcarz A
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II28-9. PubMed ID: 19813332
    [No Abstract]   [Full Text] [Related]  

  • 40. Meta-analysis of adverse cardiovascular outcomes associated with antecedent hypertension after myocardial infarction.
    Chen G; Hemmelgarn B; Alhaider S; Quan H; Campbell N; Rabi D
    Am J Cardiol; 2009 Jul; 104(1):141-7. PubMed ID: 19576336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.